Natera (NASDAQ:NTRA) Given New $200.00 Price Target at Sanford C. Bernstein

Natera (NASDAQ:NTRA) had its price objective increased by Sanford C. Bernstein from $160.00 to $200.00 in a research note released on Friday morning,Benzinga reports. They currently have an outperform rating on the medical research company’s stock.

Several other research analysts also recently issued reports on the company. TD Cowen lifted their price objective on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird boosted their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Morgan Stanley upped their price objective on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Craig Hallum lifted their price objective on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, The Goldman Sachs Group upped their target price on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $158.00.

Natera Stock Down 0.9 %

NTRA opened at $175.00 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a market cap of $23.10 billion, a price-to-earnings ratio of -99.43 and a beta of 1.65. Natera has a one year low of $59.80 and a one year high of $177.00. The business’s fifty day moving average is $159.12 and its two-hundred day moving average is $131.68.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same period in the previous year, the firm earned ($0.95) EPS. The business’s revenue for the quarter was up 63.9% compared to the same quarter last year. Analysts anticipate that Natera will post -1.61 EPS for the current fiscal year.

Insider Transactions at Natera

In other news, insider John Fesko sold 669 shares of the stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the completion of the sale, the insider now owns 114,142 shares of the company’s stock, valued at $18,217,063.20. This represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Roelof Botha sold 87,473 shares of Natera stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the transaction, the director now owns 1,224,787 shares in the company, valued at $207,135,977.44. The trade was a 6.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 127,932 shares of company stock worth $20,635,430 in the last ninety days. Insiders own 7.60% of the company’s stock.

Institutional Trading of Natera

Several large investors have recently added to or reduced their stakes in NTRA. TD Asset Management Inc acquired a new stake in shares of Natera in the second quarter valued at about $1,235,000. Quest Partners LLC grew its position in Natera by 22,861.5% in the second quarter. Quest Partners LLC now owns 2,985 shares of the medical research company’s stock valued at $323,000 after acquiring an additional 2,972 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Natera during the second quarter valued at approximately $322,000. Federated Hermes Inc. lifted its position in shares of Natera by 13.6% during the second quarter. Federated Hermes Inc. now owns 480,745 shares of the medical research company’s stock worth $52,060,000 after purchasing an additional 57,476 shares in the last quarter. Finally, Thoroughbred Financial Services LLC purchased a new position in shares of Natera in the second quarter valued at $1,380,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.